Goldman Sachs Remains Bullish on BioMarin (BMRN)

July 26, 2013 1:47 PM

Goldman Sachs today maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a price target of $76.00. The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found